Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-02-23
1996-06-18
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, 530350, 530399, C07K 200, C07K 1400, A61K 3827
Patent
active
055277764
ABSTRACT:
This invention includes a method of treating subjects with immunologic and hematologic disorders, such as immune deficiencies and anemias characterized by deficient total hemoglobin. The treatment includes administering to the subject insulin-like growth factor binding protein-3 (IGFBP-3), alone or in a complex including an insulin-like growth factor (IGF), in an amount sufficient to improve the immunologic and/or hematologic disorder, for example, increasing the level of total hemoglobin or improving immune deficiencies, such as occur post-chemotherapy. Another aspect of the invention includes administering IGFBP-3 alone to treat IGF-driven lymphoproliferative conditions, such as leukemias, inflammatory skin diseases, and nasal polyps.
REFERENCES:
patent: 4876242 (1989-10-01), Applebaum et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5202119 (1993-04-01), Clark et al.
Blum et al., "Plasma IGFBP-3 levels as clinical indicators" Modern Concepts in Insulin-like Growth Factors (1991) Spencer, E. M., ed., Elsevier Publishers, New York pp. 381-393.
Rinderknecht et al., "Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: Isolation, chemical characterization, and some biological properties of forms I and II" Proc. Natl. Acad. Sci. USA (1976) 73:2365-2369.
Baxter et al., "Growth hormone-dependent insulin-like growth factor (IGF) binding protein from human plasma differs from other human IGF binding proteins" Biochem. Biophys. Res. Commun. (1986) 139:1256-1261.
Sommer et al., "Molecular genetics and actions of recombinant insulin-like growth factor binding protein--3" Modern Concepts in Insulin-like Growth Factors (1991) Spencer, E. M., ed., Elsevier Publishers, New York, pp. 715-728.
Skottner et al., "Anabolic and tissue repair functions of recombinant insulin-like growth factor I" Acta Paediatr. Scand. (1990) 367:63-66.
Gala, "Prolactin and growth hormone in the regulation of the immune system" PSEBM (1991) 198:513-527.
Murphy et al., "Immunologic and hematologic effects of neuroendocrine hormones" J. Immunol. (1992) 148:3799-3805.
Binz et al., "Repopulation of the atrophied thymus in diabetic rats by insulin-like growth factor I" Proc. Natl. Acad. Sci. USA (1990) 87:3690-3694.
Hodgkinson et al., "Distribution of circulating insulin-like growth factor I (IGF-I)" into tissues Endocrinology (1991) 129(4):2085-2093.
Beschocmer et al., "Enhancement of thymic recovery after cyclosporine by recombinant human growth hormone and insulin-like growth factor I" Transplantation (1991) 52(2):879-884.
Aron et al., "Insulin-like growth factor I and erythropoiesis" BioFactors (1992) 3(4):211-216.
Quaife et al., "Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice" Endocrinology (1989) 124(1):40-48.
Intebi et al., "Active B-Cell differentiation under PWM induction acromegaly" Prog. Neuroendoimmunol. (1992) 5(1):62-69.
Jennische et al., "Dynamic changes in insulin-like growth factor I immunoreactivity correlate to repair events in rat ear after freeze-thaw injury" Exp. Mol. Pathol. (1987) 47:193-201.
Spencer et al., "Somatomedins: Do they play a pivotal role in wound healing?" Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications (1988) Alan R. Liss Publishers, pp. 103-116.
Baxter et al., "Characterization of immunoreactive insulin-like growth factor-I from leukocytes and its regulation by growth hormone" Endocrinol. (1991) 129(4):1727-1734.
Stuart et al., "Insulin-like growth factor-I binds selectively to human peripheral blood monocytes and B-lymphocytes" J. Clin. Endocrinol. Metab. (1991) 72(5):1117-1122.
Kooijman et al., "Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells" Endocrinol. (1992) 131:2244-2250.
Marchav et al., "Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor I/sometomedin C and human growth hormone" J. Clin. Invest. (1988) 81:791-797.
Zapf et al., "In vivo models of IGF binding protein (IGFBP) regulation with possible relevance to their physiological roles" Modern Concepts in Insulin-like Growth Factors (1991) Spencer, E. M., ed., Elsevier Publishers, New York, pp. 591-605.
Kooijman et al., "Effects of insulin-like growth factors and growth hormone on the in vitro proliferation of T lymphocytes" J. Neuroimmunol. (1992) 38:95-104.
Neely et al., "Mitogenic effects of human recombinant insulin on B-cell precursor acute lymphoblastic leukemia cells" Leukemia (1992) 6(11):1134-1142.
Krane et al., "Insulin-like growth factor-I (IGF-I) receptor expression may regulate keratinocyte proliferative potential in normal and psoriatic epidermis" J. Invest. Dermatol. (1991) 96(4):544A (abstract No. 71).
Geffner et al., "Growth hormone mediates the growth of T-lymphoblast cell lines via locally generated insulin-like growth factor-I" J. Clin. Endocrinol. (1990) 71(2):464-469.
Liu et al., "Insulin-like growth factor binding protein (IGFBP-3), an inhibitor of serum growth factors other than IGF-I and -II" J. Cell. Physiol. (1992) 153:15-21.
Cohen et al., "Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth" Mol. Endocrinol. (1993) 7:380-386.
Barak et al., "Enhanced response of human circulating erythroid progenitor cells to hGH and to IGF-I in children with insufficient growth hormone secretion" Pediatric Res. (1992) 32(3):282-285.
Boyer et al., "Roles of erythropoietin, insulin-like growth factor I, and unidentified serum factors in promoting maturation of purified murine erythroid colony-forming units" Blood (1992) 80(10):2503-2512.
Bozzola et al., "Immunological and endocrinological response to growth hormone therapy in short children" Acta Pediatr. Scand. (1988) 77:675-680.
Chatelain et al., "Paracraine and autocrine regulation of insulin-like growth factor I" Acta Pediatr. Scand. (1991) 372:92-95.
Fu et al., "A novel role of growth hormone and insulin-like growth factor-I" J. Immunol. (1991) 146(5):1602-1608.
Huang et al., "Formation of haematopoietic microenvironment and haematopoietic stem cells from single human bone marrow stem cells" Nature (1992) 360:745-749.
Landreth et al., "Insulin-like growth factor-I regulates Pro-B cell differentiation" Blood (1992) 80(5):1207-1212.
Merchav et al., "Comparative studies of the erythroid-potentiating effects of biosynthetic human insulin-like growth factors-I and II" J. Clin. Endocrinol. Metab. (1992) 74(2):447-451.
Miller et al., "Alterations of erythropoiesis in TGF-.beta.1-treated mice" Exp. Hematol. (1992) 20:951-956.
Urena et al., "Insulin-like growth factor I: A Moderator of erythropoiesis in uraemic patients?" Nephrol. Dial. Transplant. (1992) 7:40-44.
Baxter, Comp. Biochem. Physiol. vol. 91B, No. 2, 229-235, 1991.
Bioventure View, vol. IV, No. 1, 19-24, 1989.
Werther et al., "Insulin-like growth factors promote DNA synthesis and support cell viability in fetal hemopoietic tissue by paracrine mechanisms" Growth Factors (1990) 3:171-179.
Carlino Joseph A.
Higley Howard R.
Maack Christopher A.
Celtrix Pharmaceuticals
Schain Howard E.
Touzeau Lynn
LandOfFree
Treatment of immunologic and hematologic disorders with IGFBP al does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of immunologic and hematologic disorders with IGFBP al, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of immunologic and hematologic disorders with IGFBP al will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-222910